GlobeNewswire·Mar 23, 2026, 8:00 AM ET

Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering

Reviva Pharmaceuticals Holdings, Inc. closed a public offering on March 20, 2026, selling 6,666,667 shares of common stock & accompanying Series G & Series H warrants.
The combined offering price was $1.50 per share & accompanying warrants, generating approximately $10 million in aggregate gross proceeds before fees & expenses.
Both Series G & Series H warrants carry an exercise price of $1.50 per share & are exercisable immediately upon issuance.
Series G Warrants expire five years from the issuance date, while Series H Warrants expire 12 months from the issuance date.
Net proceeds will fund research & development activities, including the planned RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia, plus working capital & general corporate purposes.
Post-offering cash & cash equivalents total approximately $23 million, which the company expects to sustain operations into Q1-2027.
A.G.P./Alliance Global Partners served as the sole placement agent for the offering.
The securities were offered pursuant to an effective Form S-3 shelf registration statement filed with the SEC on February 2, 2024.
Reviva is a late-stage biopharmaceutical company focusing on CNS, inflammatory, & cardiometabolic diseases with a pipeline including brilaroxazine & RP1208.